EV20, a novel anti-ErbB-3 humanized antibody, promotes ErbB-3 down-regulation and inhibits tumor growth In vivo

Translational Oncology

Volumn 6, Issue 6, 2013, Pages 676-684

  Sala, Gianluca ^a,b   Rapposelli, Ilario Giovanni ^b   Ghasemi, Reza ^b,c   Piccolo, Enza ^a,b   Traini, Sara ^a,b   Capone, Emily ^b   Rossi, Cosmo ^b   Pelliccia, Angela ^d   Risio, Annalisa Di ^a,b   D'Egidio, Maurizia ^b   Tinari, Nicola ^a,b   Muraro, Raffaella ^a,b   Iacobelli, Stefano ^a,b  

^a MediaPharma srl   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EV 20; MONOCLONAL ANTIBODY; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTIBODY SCREENING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL TYPE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIMERIZATION; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURFACE PLASMON RESONANCE; TUMOR VOLUME;

EID: 84891683320     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13475     Document Type: Article

References (37)

1. Sharma SV and Settleman J (2009). ErbBs in lung cancer. Exp Cell Res 315, 557-571.
2. Wu WK, Tse TT, Sung JJ, Li ZJ, Yu L, and Cho CH (2009). Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. Anticancer Res 29, 229-234.
3. Hynes NE and MacDonald G (2009). ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21, 177-184.
4. Hynes NE and Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5, 341-354.
5. Holbro T, Civenni G, and Hynes NE (2003). The ErbB receptors and their role in cancer progression. Exp Cell Res 284, 99-110.
6. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, and Hortobagyi GN (2009). The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14, 320-368.
7. Robinson KW and Sandler AB (2013). EGFR tyrosine kinase inhibitors: difference in efficacy and resistance. Curr Oncol Rep 15, 396-404.
8. Shi F, Telesco SE, Liu Y, Radhakrishnan R, and Lemmon MA (2010). ErbB3/ HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 107, 7692-7697.
9. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, and Amir E (2012). HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst 105, 266-273.
10. Cook RS, Garrett JT, Sánchez V, Stanford JC, Young C, Chakrabarty A, Rinehart C, Zhang Y, Wu Y, Greenberger L, et al. (2011). ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res 71, 3941-3951.
11. Campbell MR, Amin D, and Moasser MM (2010). HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 16, 1373-1383.
12. Wimmer E, Kraehn-Senftleben G, and Issing WJ (2008). HER3 expression in cutaneous tumors. Anticancer Res 28, 973-979.
13. Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H, and Ullrich A (2008). HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 14, 5188-5197.
14. Grivas PD, Antonacopoulou A, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou AG, and Kalofonos H (2007). HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships. Eur J Cancer 43, 2602-2611.
15. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, et al. (2006). ErbB-3 predicts survival in ovarian cancer. J Clin Oncol 24, 4317-4323.
16. Prigent SA and Gullick WJ (1994). Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 13, 2831-2841.
17. Manning BD and Cantley LC (2007). AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274.
18. Baselga J and Swain SM (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9, 463-475.
19. Aurisicchio L, Marra E, Roscilli G, Mancini R, and Ciliberto G (2012). The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget 3, 744-758.
20. Lazrek Y, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, Thomas G, Leconet W, Jarlier M, Pugnière M, et al. (2013). Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Neoplasia 15, 335-347.
21. Lorusso P, Jänne PA, Oliveira M, Rizvi N, Malburg L, Keedy V, Yee L, Copigneaux C, Hettmann T, Wu CY, et al. (2013). Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 19, 3078-3087.
22. Sala G, Traini S, D'Egidio M, Vianale G, Rossi C, Piccolo E, Lattanzio R, Piantelli M, Tinari N, Natali PG, et al. (2012). An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. Oncogene 31, 1275-1286.
23. Petronzelli F, Pelliccia A, Anastasi AM, D'Alessio V, Albertoni C, Rosi A, Leoni B, De Angelis C, Paganelli G, Palombo G, et al. (2005). Improved tumor targeting by combined use of two antitenascin antibodies. Clin Cancer Res 11, 7137s-7145s.
24. Leonetti C, D'Agnano I, Lozupone F, Valentini A, Geiser T, Zon G, Calabretta B, Citro GC, and Zupi G (1996). Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J Natl Cancer Inst 88, 419-429.
25. Rege-Cambrin G, Scaravaglio P, Carozzi F, Giordano S, Ponzetto C, Comoglio PM, and Saglio G (1992). Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. Cancer Genet Cytogenet 64, 170-173.
26. Sala G, Dituri F, Raimondi C, Previdi S, Maffucci T, Mazzoletti M, Rossi C, Iezzi M, Lattanzio R, Piantelli M, et al. (2008). Phospholipase Cγ1 is required for metastasis development and progression. Cancer Res 68, 10187-10196.
27. Li N, Hill KS, and Elferink LA (2008). Analysis of receptor tyrosine kinase internalization using flow cytometry. Methods Mol Biol 457, 305-317.
28. Arai K, Yoshinari K, Matsumoto K, and Misaki H (1998). An ELISA to determine the biodistribution of human monoclonal antibody in tumor-xenografted SCID mice. J Immunol Methods 217, 79-85.
29. Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA, et al. (2013). Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23, 603-617.
30. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043.
31. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, and Moasser MM (2007). Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437-441.
32. Chakrabarty A, Sanchez V, Kuba MG, Rinehart C, and Arteaga CL (2012). Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA 109, 2718-2723.
33. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, et al. (2011). Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 108, 5021-5026.
34. Abel EV, Basile KJ, Kugel CH, Witkiewicz AK, Le K, Amaravadi RK, Karakousis GC, Xu X, Xu W, Schuchter LM, et al. (2013). Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest 123, 2155-2168.
35. Vaswani SK and Hamilton RG (1998). Humanized antibodies as potential therapeutic drugs. Ann Allergy Asthma Immunol 81, 105-115; quiz 115-106, 119.
36. Kipriyanov SM and Little M (1999). Generation of recombinant antibodies. Mol Biotechnol 12, 173-201.
37. Sievers EL and Senter PD (2012). Antibody-drug conjugates in cancer therapy. Annu Rev Med 64, 15-29.